Search tips
Search criteria 


Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. 2002 April; 61(4): 346–350.
PMCID: PMC1754050

Influence of prior pregnancies on disease course and cause of death in systemic sclerosis


Background: Microchimerism from fetal or maternal cells transferred during pregnancy has been implicated in the pathogenesis of systemic sclerosis (SSc).

Objective: To determine whether a prior pregnancy influenced disease progression and cause of death in patients with SSc.

Patients and methods: The patients comprised a retrospective study cohort of 111 women with SSc: 78 patients with prior pregnancies (PP) and 33 who were never pregnant (NP), followed up at Thomas Jefferson University. Differences in age at onset, disease subset, organ involvement, cause of death, and type of antinuclear autoantibodies were evaluated statistically, including regression analysis.

Results: The age at onset of SSc in NP patients was 32.0 years compared with 45.7 years in patients with one or two prior pregnancies (p<0.0001), 46.6 years in patients with three or four pregnancies (p<0.0001), and 51.3 years in patients with five to seven pregnancies (p<0.0005). In the 16 patients who had an elective pregnancy termination, 14/16 (87.5%) had diffuse SSc v 2/16 (12.5%) with limited SSc (p<0.0001; odds ratio (OR)=49.0). Of the NP women, 7/30 (23%) died from SSc related causes v 3/78 (4%) women who had pregnancies (p=0.0058; OR=7.6). A carbon monoxide transfer factor (TLCO) of <60% and disease duration >10 years was found in 10/13 (77%) NP patients v 10/23 (43%) patients who had pregnancies (p=0.05; OR=4.7), and a TLCO <50% and disease duration >10 years was identified in 7/13 (54%) NP patients v 6/23 (26%) of the patients who had pregnancies (p=0.09; OR=3.2).

Conclusions: There are differences in the age at onset, clinical course, severity of lung involvement, and cause of death in women who develop SSc before pregnancy compared with those who develop it after pregnancies. The NP patients with SSc had onset of disease at an earlier age, more severe lung involvement, and higher rate of death due to SSc.

Full Text

The Full Text of this article is available as a PDF (116K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Collagen. Rheum Dis Clin North Am. 1996 Nov;22(4):647–674. [PubMed]
  • LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am. 1996 Nov;22(4):675–694. [PubMed]
  • Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am. 1996 Nov;22(4):709–735. [PubMed]
  • Siimes MA, Johansson E, Rapola J. Scleroderma-like graft-versus-host disease as late consequence of bone-marrow grafting. Lancet. 1977 Oct 15;2(8042):831–832. [PubMed]
  • Lawley TJ, Peck GL, Moutsopoulos HM, Gratwohl AA, Deisseroth AB. Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med. 1977 Dec;87(6):707–709. [PubMed]
  • Artlett CM, Smith JB, Jimenez SA. New perspectives on the etiology of systemic sclerosis. Mol Med Today. 1999 Feb;5(2):74–78. [PubMed]
  • Fleischmajer R, Perlish JS, Reeves JR. Cellular infiltrates in scleroderma skin. Arthritis Rheum. 1977 May;20(4):975–984. [PubMed]
  • Lambert IA, Suitters AJ, Janossy G, Thomas JA, Palmer S, Gordon Smith E. Lymphoid infiltrates in skin in graft-versus-host disease. Lancet. 1981 Dec 12;2(8259):1352–1352. [PubMed]
  • Jiménez SA. Cellular immune dysfunction and the pathogenesis of scleroderma. Semin Arthritis Rheum. 1983 Aug;13(1 Suppl 1):104–113. [PubMed]
  • Kahaleh MB, LeRoy EC. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann Intern Med. 1989 Mar 15;110(6):446–450. [PubMed]
  • Fagundus DM, Leroy EC. Cytokines and systemic sclerosis. Clin Dermatol. 1994 Jul-Sep;12(3):407–417. [PubMed]
  • Postlethwaite AE. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol. 1993 Nov;5(6):766–772. [PubMed]
  • Janin-Mercier A, Devergie A, Van Cauwenberge D, Saurat JH, Bourges M, Lapiere CM, Gluckman E. Immunohistologic and ultrastructural study of the sclerotic skin in chronic graft-versus-host disease in man. Am J Pathol. 1984 May;115(2):296–306. [PubMed]
  • Silman AJ, Black C. Increased incidence of spontaneous abortion and infertility in women with scleroderma before disease onset: a controlled study. Ann Rheum Dis. 1988 Jun;47(6):441–444. [PMC free article] [PubMed]
  • Black CM, Stevens WM. Scleroderma. Rheum Dis Clin North Am. 1989 May;15(2):193–212. [PubMed]
  • Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):705–708. [PubMed]
  • Nelson JL. Maternal-fetal immunology and autoimmune disease: is some autoimmune disease auto-alloimmune or allo-autoimmune? Arthritis Rheum. 1996 Feb;39(2):191–194. [PubMed]
  • Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med. 1998 Apr 23;338(17):1186–1191. [PubMed]
  • Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A, Bean MA, Ober C, Bianchi DW. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet. 1998 Feb 21;351(9102):559–562. [PubMed]
  • JOHNSON TR, BANNER EA, WINKELMANN RK. SCLERODERMA AND PREGNANCY. Obstet Gynecol. 1964 Mar;23:467–469. [PubMed]
  • Slate WG, Graham AR. Scleroderma and pregnancy. Am J Obstet Gynecol. 1968 Jun 1;101(3):335–341. [PubMed]
  • Steen VD. Scleroderma and pregnancy. Rheum Dis Clin North Am. 1997 Feb;23(1):133–147. [PubMed]
  • Goplerud CP. Scleroderma. Clin Obstet Gynecol. 1983 Sep;26(3):587–591. [PubMed]
  • Shimaoka Y, Hidaka Y, Tada H, Nakamura T, Mitsuda N, Morimoto Y, Murata Y, Amino N. Changes in cytokine production during and after normal pregnancy. Am J Reprod Immunol. 2000 Sep;44(3):143–147. [PubMed]
  • Piccinni MP, Scaletti C, Maggi E, Romagnani S. Role of hormone-controlled Th1- and Th2-type cytokines in successful pregnancy. J Neuroimmunol. 2000 Sep 1;109(1):30–33. [PubMed]
  • Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol. 1993 Nov 1;151(9):4562–4573. [PubMed]
  • Hartwell D, Levine J, Fenton M, Francis C, Leslie C, Beller D. Cytokine dysregulation and the initiation of systemic autoimmunity. Immunol Lett. 1994 Dec;43(1-2):15–21. [PubMed]
  • Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May;23(5):581–590. [PubMed]
  • LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988 Feb;15(2):202–205. [PubMed]
  • Lally EV, Jimenez SA, Kaplan SR. Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum. 1988 Aug;18(1):1–13. [PubMed]
  • Silman AJ. Pregnancy and scleroderma. Am J Reprod Immunol. 1992 Oct-Dec;28(3-4):238–240. [PubMed]
  • Reinhard G, Noll A, Schlebusch H, Mallmann P, Ruecker AV. Shifts in the TH1/TH2 balance during human pregnancy correlate with apoptotic changes. Biochem Biophys Res Commun. 1998 Apr 28;245(3):933–938. [PubMed]
  • Deneys V, De Bruyere M. Immunological tolerance of the fetal allograft: efficacy of immunotherapy and IL-4 and TNF alpha serum levels in recurrent abortion. Transplant Proc. 1997 Aug;29(5):2467–2469. [PubMed]
  • Artlett CM, Welsh KI, Black CM, Jimenez SA. Fetal-maternal HLA compatibility confers susceptibility to systemic sclerosis. Immunogenetics. 1997;47(1):17–22. [PubMed]
  • Liegeois A, Gaillard MC, Ouvre E, Lewin D. Microchimerism in pregnant mice. Transplant Proc. 1981 Mar;13(1 Pt 2):1250–1252. [PubMed]
  • Suzumori K, Adachi R, Okada S, Narukawa T, Yagami Y, Sonta S. Fetal cells in the maternal circulation: detection of Y-sequence by gene amplification. Obstet Gynecol. 1992 Jul;80(1):150–154. [PubMed]
  • Maloney S, Smith A, Furst DE, Myerson D, Rupert K, Evans PC, Nelson JL. Microchimerism of maternal origin persists into adult life. J Clin Invest. 1999 Jul;104(1):41–47. [PMC free article] [PubMed]
  • Artlett CM, Ramos R, Jiminez SA, Patterson K, Miller FW, Rider LG. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet. 2000 Dec 23;356(9248):2155–2156. [PubMed]
  • Launay D, Hebbar M, Hatron PY, Michon-Pasturel U, Queyrel V, Hachulla E, Devulder B. Relationship between parity and clinical and biological features in patients with systemic sclerosis. J Rheumatol. 2001 Mar;28(3):509–513. [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group